31.89

1.02% -0.33

After Hours: 31.89

Stoke Therapeutics Inc (STOK)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Stoke Therapeutics Inc stock is traded at $31.89, with a volume of 450.84K. It is down -1.02% in the last 24 hours and up +8.40% over the past month. Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Previous Close:

$32.22

Open:

$32.95

24h Volume:

450.84K

Relative Volume:

0.56

Market Cap:

$1.82B

Revenue:

$199.89M

Net Income/Loss:

$52.48M

P/E Ratio:

37.52

EPS:

0.85

Net Cash Flow:

$61.15M

1W Performance:

+4.63%

1M Performance:

+8.40%

6M Performance:

+135.70%

1Y Performance:

+210.82%

1-Day Range:

$31.46

$33.28

1-Week Range:

$30.75

$33.48

52-Week Range:

$5.35

$38.69

Stoke Therapeutics Inc Stock (STOK) Company Profile

Name

Stoke Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

781-430-8200

Address

45 WIGGINS AVENUE, BEDFORD, MA

Employee

128

Twitter

@stoketx

Next Earnings Date

2025-03-18

Latest SEC Filings

STOK's Discussions on Twitter

Compare STOK vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
STOK Stoke Therapeutics Inc	31.89	1.84B	199.89M	52.48M	61.15M	0.85
VRTX Vertex Pharmaceuticals Inc	465.02	117.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	783.65	82.35B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	833.54	51.64B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	308.48	42.58B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.42	38.87B	4.98B	69.60M	525.67M	0.5198

Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-05-26	Initiated	Guggenheim	Buy
Jan-05-26	Resumed	Chardan Capital Markets	Buy
Jul-18-25	Initiated	Jefferies	Buy
Dec-20-24	Initiated	Chardan Capital Markets	Buy
Oct-14-24	Resumed	Leerink Partners	Outperform
Mar-26-24	Upgrade	TD Cowen	Market Perform → Outperform
Nov-20-23	Resumed	JP Morgan	Neutral
Jul-25-23	Downgrade	TD Cowen	Outperform → Market Perform
May-01-23	Upgrade	BofA Securities	Underperform → Neutral
Apr-26-23	Resumed	Canaccord Genuity	Buy
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform
Oct-24-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jan-31-22	Initiated	Jefferies	Buy
Dec-03-21	Initiated	BofA Securities	Buy
Nov-22-21	Upgrade	JP Morgan	Neutral → Overweight
May-18-21	Initiated	UBS	Neutral
May-10-21	Upgrade	Wedbush	Neutral → Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform
Feb-10-21	Downgrade	Wedbush	Outperform → Neutral
Dec-15-20	Resumed	H.C. Wainwright	Buy
Dec-11-20	Reiterated	Needham	Buy
Oct-23-20	Initiated	Cantor Fitzgerald	Overweight
Sep-29-20	Resumed	JP Morgan	Neutral
Sep-29-20	Initiated	Needham	Buy
Dec-18-19	Initiated	Wedbush	Outperform
Nov-12-19	Initiated	BTIG Research	Buy
Oct-25-19	Initiated	H.C. Wainwright	Buy
Jul-15-19	Initiated	Canaccord Genuity	Buy
Jul-15-19	Initiated	Cowen	Outperform
Jul-15-19	Initiated	Credit Suisse	Outperform
Jul-15-19	Initiated	JP Morgan	Overweight

View All

Stoke Therapeutics Inc Stock (STOK) Latest News

04:07 AM

Ideas Watch: What is the earnings history of Stoke Therapeutics IncQuarterly Trade Review & AI Enhanced Market Trend Forecasts - baoquankhu1.vn

04:07 AM

Feb 11, 2026

STOK: Four-year data show durable seizure reduction and cognitive gains, with phase 3 readout expected 2027 - TradingView

Feb 11, 2026

Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Mo - pharmiweb.com

Feb 11, 2026

Stoke Therapeutics announces first patient dosed in Phase 1 study of STK-002 - marketscreener.com

Feb 11, 2026

Stoke Therapeutics announced that the dose-escalation phase for the first four cohorts of its research project will continue into 2026 and early 2027. - Bitget

Feb 11, 2026

Stoke Therapeutics Announces First Patient Dosed In Phase 1 Study Of Stk-002 - TradingView

Feb 11, 2026

Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA) - Business Wire

Feb 11, 2026

Feb 10, 2026

Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Feb 10, 2026

Feb 07, 2026

Quarterly Earnings: What is the PEG ratio of Stoke Therapeutics IncJuly 2025 Movers & Fast Gain Stock Trading Tips - baoquankhu1.vn

Feb 07, 2026

Guggenheim Upgrades Stoke Therapeutics (NASDAQ:STOK) to "Strong-Buy" - MarketBeat

Feb 07, 2026

Feb 06, 2026

Why (STOK) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Feb 06, 2026

Earnings Recap: How does Stoke Therapeutics Inc score in quality rankingsShare Buyback & Target Return Focused Stock Picks - baoquankhu1.vn

Feb 06, 2026

Penserra Capital Management LLC Acquires New Position in Stoke Therapeutics, Inc. $STOK - MarketBeat

Feb 06, 2026

Feb 05, 2026

Stoke Therapeutics stock jumps after Guggenheim initiates with Buy rating By Investing.com - Investing.com South Africa

Feb 05, 2026

Stoke Therapeutics stock jumps after Guggenheim initiates with Buy rating - Investing.com

Feb 05, 2026

Guggenheim Initiates Coverage on Stoke Therapeutics With Buy Rating, $60 Price Target - marketscreener.com

Feb 05, 2026

Guggenheim initiates Stoke Therapeutics stock with Buy rating on Dravet drug - Investing.com Canada

Feb 05, 2026

Feb 04, 2026

Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - pharmiweb.com

Feb 04, 2026

Feb 03, 2026

Aug Action: Can Stoke Therapeutics Inc navigate macro headwindsEarnings Miss & Growth-Oriented Investment Plans - baoquankhu1.vn

Feb 03, 2026

Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock? - MSN

Feb 03, 2026

Jan 31, 2026

Sentiment Watch: Should I hold or sell Stoke Therapeutics Inc nowJuly 2025 Opening Moves & Weekly Breakout Watchlists - baoquankhu1.vn

Jan 31, 2026

Breakouts Watch: Does FULT outperform in volatile marketsJuly 2025 Opening Moves & Daily Volume Surge Trade Alerts - baoquankhu1.vn

Jan 31, 2026

Jan 30, 2026

Commit To Buy Stoke Therapeutics At $20, Earn 20.2% Annualized Using Options - Nasdaq

Jan 30, 2026